Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for business professionals · Wednesday, January 29, 2020 · 508,349,654 Articles · 3+ Million Readers

2020 US Drug Patent Litigation Research

/EIN News/ -- Dublin, Jan. 09, 2020 (GLOBE NEWSWIRE) -- The "Drug Patent Database Subscription: US Drug Patent Litigation" newsletter has been added to's offering.

Global biopharmaceutical markets face constant change. To remain competitive you need to anticipate what's next. If you are expanding into new markets, looking inward for growth opportunities, or seeking to improve your current activities and need to find information quickly, this subscription can help.

This subscription for the US Drug Patent Litigation portion of the database offers information on:

  • US District Court Cases, Patent Infringement, Contract Disputes, Antitrust, etc.
  • Patent Trial and Appeal Board, PTAB inter partes review, post-grant review

The subscription includes relevant context and ensures you have the information you need at your fingertips. This helps you see opportunities and enrich your analysis, without overwhelming you with options or asking you to perform many searches. The sophisticated algorithms are also tailored to help you extract valuable insights.

With a single click, you can find answers to complex questions such as:

  • Which drugs have no patents and no competitors?
  • What are all the patents covering any given dosage form (e.g. injectables)?
  • What is the earliest generic entry opportunity date for a drug with dozens of patents?

The subscription focuses on delivering the greatest value and lowest cost by directing attention to high-impact problems, giving you the relevant information you need.

Key Topics Covered:

  • US District Court Cases
  • Patent Infringement, Contract Disputes, Antitrust, etc.
  • Patent Trial and Appeal Board

Some of the Companies Mentioned Include:

  • 3M Pharmaceuticals
  • Abbott Laboratories
  • AbbVie
  • Acorda Therapeutics
  • Actavis
  • Allergan
  • Almirall
  • Amgen
  • Anfatis
  • Astellas Pharma
  • AstraZeneca
  • Avax Technologies
  • Biocon
  • Biolex
  • Bionovo
  • Biotecnol
  • Boehringer-Ingelheim
  • Bosnalijek
  • Bristol-Myers Squibb
  • BTG plc
  • Cadila Healthcare
  • Catalent
  • The Cathay Drug Co., Inc.
  • Celgene
  • Cephalon
  • Chugai Pharmaceutical Co.
  • CinnaGen
  • Cipla
  • CoCo Therapeutics
  • Concordia Healthcare
  • Dabur
  • Daiichi Sankyo
  • Diabetology Ltd
  • Dr. Reddy's Laboratories
  • Eisai
  • Elder Pharmaceuticals
  • Galderma Laboratories
  • Gedeon Richter Ltd.
  • Gilead Sciences
  • Glatt group
  • GlaxoSmithKline
  • GPC Biotech
  • Hovione
  • Interphil Laboratories
  • Ionis Pharmaceuticals
  • Ipca Laboratories
  • Ipsen
  • Janssen Pharmaceutica
  • Jenapharm
  • Johnson & Johnson
  • Julphar
  • Juno Therapeutics
  • Kimia Farma
  • McGuff
  • Medinfar
  • Melior Discovery
  • Menarini
  • Merck & Co.
  • Mitsubishi Pharma
  • Novartis
  • Novo Nordisk
  • Noxxon
  • Otsuka Pharmaceutical Co.
  • Panacea Biotec
  • Patheon
  • Perrigo
  • Pfizer
  • Procter & Gamble
  • Purdue Pharma
  • Ranbaxy Laboratories
  • Reckitt Benckiser
  • Renovo PLC
  • Repligen
  • Rubicon Research
  • Salix Pharmaceuticals
  • Sanofi
  • Servier Laboratories
  • Shionogi
  • Shire plc
  • SIGA Technologies
  • Sigma Pharmaceuticals
  • Sinopharm Group
  • Solvay Group
  • Sun Pharmaceutical
  • Sunovion
  • Takeda Pharmaceutical Co.
  • Tasly
  • Teva Pharmaceuticals
  • UCB
  • Unichem Laboratories
  • USV Private Limited
  • Wockhardt
  • Yuhan Corporation

For more information about this newsletter visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                             Laura Wood, Senior Press Manager
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900

Primary Logo

Powered by EIN News
Distribution channels: Culture, Society & Lifestyle, Science

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release